JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

14.17 1.29

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

13.72

Max

14.17

Galvenie mērījumi

By Trading Economics

Ienākumi

3.9M

4.5M

Pārdošana

5.9M

24M

EPS

0.35

Dividenžu ienesīgums

0.48

Peļņas marža

18.669

Darbinieki

212

EBITDA

4.9M

7.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+14.37% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.36%

Nākamie ieņēmumi

2026. g. 13. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

44M

295M

Iepriekšējā atvēršanas cena

12.88

Iepriekšējā slēgšanas cena

14.17

Ziņu noskaņojums

By Acuity

24%

76%

65 / 347 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. apr. 23:08 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 23:07 UTC

Peļņas

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:20 UTC

Peļņas

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 23:48 UTC

Tirgus saruna

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026. g. 30. apr. 23:27 UTC

Tirgus saruna

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026. g. 30. apr. 23:22 UTC

Peļņas

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026. g. 30. apr. 23:20 UTC

Tirgus saruna

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026. g. 30. apr. 22:52 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:33 UTC

Peļņas

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026. g. 30. apr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026. g. 30. apr. 22:05 UTC

Peļņas

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 21:57 UTC

Peļņas

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026. g. 30. apr. 21:55 UTC

Peļņas

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026. g. 30. apr. 21:53 UTC

Peļņas

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

14.37% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD  14.37%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

65 / 347 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat